AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Statistics
Share Statistics
AIM ImmunoTech has 68.75M shares outstanding. The number of shares has increased by 30.58% in one year.
| Shares Outstanding | 68.75M |
| Shares Change (YoY) | 30.58% |
| Shares Change (QoQ) | 11.63% |
| Owned by Institutions (%) | 15.63% |
| Shares Floating | 60.91M |
| Failed to Deliver (FTD) Shares | 7.12K |
| FTD / Avg. Volume | 0.69% |
Short Selling Information
The latest short interest is 491.37K, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 491.37K |
| Short % of Shares Out | 0.73% |
| Short % of Float | 0.82% |
| Short Ratio (days to cover) | 1.63 |
Valuation Ratios
The PE ratio is -0.74 and the forward PE ratio is -0.54. AIM ImmunoTech's PEG ratio is -0.02.
| PE Ratio | -0.74 |
| Forward PE | -0.54 |
| PS Ratio | 105.81 |
| Forward PS | 0.2 |
| PB Ratio | 2.09 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | -0.02 |
Enterprise Valuation
AIM ImmunoTech Inc. has an Enterprise Value (EV) of 16.65M.
| EV / Earnings | -0.57 |
| EV / Sales | 82.43 |
| EV / EBITDA | -0.53 |
| EV / EBIT | -0.52 |
| EV / FCF | -0.76 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.68 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.56 |
| Cash Flow / Debt | -29.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.83% and return on capital (ROIC) is -291.42%.
| Return on Equity (ROE) | -2.83% |
| Return on Assets (ROA) | -1.49% |
| Return on Capital (ROIC) | -291.42% |
| Revenue Per Employee | $7,769.23 |
| Profits Per Employee | $-1,113,923.08 |
| Employee Count | 26 |
| Asset Turnover | 0.01 |
| Inventory Turnover | -0.14 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -69.62% in the last 52 weeks. The beta is 0.41, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -69.62% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 34.87 |
| Average Volume (20 Days) | 1.03M |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 202K and earned -28.96M in profits. Earnings per share was -0.6.
| Revenue | 202K |
| Gross Profit | 160K |
| Operating Income | -31.92M |
| Net Income | -28.96M |
| EBITDA | -31.68M |
| EBIT | -31.92M |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 5.44M in cash and 718K in debt, giving a net cash position of 4.72M.
| Cash & Cash Equivalents | 5.44M |
| Total Debt | 718K |
| Net Cash | 4.72M |
| Retained Earnings | -409.51M |
| Total Assets | 13.59M |
| Working Capital | -2.53M |
Cash Flow
In the last 12 months, operating cash flow was -21.27M and capital expenditures -585K, giving a free cash flow of -21.85M.
| Operating Cash Flow | -21.27M |
| Capital Expenditures | -585K |
| Free Cash Flow | -21.85M |
| FCF Per Share | -0.45 |
Margins
Gross margin is 79.21%, with operating and profit margins of -15.8K% and -14.34K%.
| Gross Margin | 79.21% |
| Operating Margin | -15.8K% |
| Pretax Margin | -14.34K% |
| Profit Margin | -14.34K% |
| EBITDA Margin | -15.68K% |
| EBIT Margin | -15.8K% |
| FCF Margin | -10.82K% |
Dividends & Yields
AIM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -500% |
| FCF Yield | -262.23% |
Analyst Forecast
The average price target for AIM is $2.75, which is 2191.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.75 |
| Price Target Difference | 2191.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 11, 2019. It was a backward split with a ratio of 1:44.
| Last Split Date | Jun 11, 2019 |
| Split Type | backward |
| Split Ratio | 1:44 |
Scores
| Altman Z-Score | -49.14 |
| Piotroski F-Score | 3 |